Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 2/2010

01-03-2010

β-Lactamase–Producing Bacteria in Upper Respiratory Tract Infections

Author: Itzhak Brook

Published in: Current Infectious Disease Reports | Issue 2/2010

Login to get access

Abstract

β-Lactamase–producing bacteria (BLPB) can play an important role in respiratory infections. They can have a direct pathogenic impact in causing the infection as well as an indirect effect through their ability to produce the enzyme β-lactamase. BLPB not only may survive penicillin therapy, but as demonstrated by in vitro and in vivo studies, can also protect other penicillin-susceptible bacteria from penicillin by releasing the free enzyme into their environment. The clinical in vitro and in vivo evidence supporting the role of these organisms in the increased failure rate of penicillin in eradication of these infections and the implication of that increased rate on the management of infections is discussed.
Literature
1.
Macgowan AP, BSAC Working Parties on Resistance Surveillance: Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 2008, 62(Suppl 2):ii105–ii114.
2.
Harrison CJ, Woods C, Stout G, et al.: Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. J Antimicrob Chemother 2009, 63:511–519.CrossRefPubMed
3.
Brook I, Calhoun L, Yocum P: Beta-lactamase-producing isolates of Bacteroides species from children. Antimicrob Agents Chemother 1980, 18:264–266.
4.
Brook I: The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection. Rev Infect Dis 1984, 6:601–607.PubMed
5.
Hackman AS, Wilkins TD: In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis. Antimicrob Agents Chemother 1975, 7:698–703.PubMed
6.
Brook I, Pazzaglia G, Coolbaugh JC, Walker RI: In vivo protection of group A beta-hemolytic streptococci by beta-lactamase producing Bacteroides species. J Antimicrob Chemother 1983, 12:599–606.CrossRefPubMed
7.
Brook I, Pazzaglia G, Coolbaugh JC, Walker RI: In vivo protection of penicillin susceptible Bacteroides melaninogenicus from penicillin by facultative bacteria which produce beta-lactamase. Can J Microbiol 1984, 30:98–104.PubMed
8.
Simon HM, Sakai W: Staphylococcal antagonism to penicillin-G therapy of hemolytic streptococcal pharyngeal infection. Effect of oxacillin. Pediatrics 1963, 31:463–469.PubMed
9.
Scheifele DW, Fussell SJ: Frequency of ampicillin resistant Haemophilus parainfluenzae in children. J Infect Dis 1981, 143:495–498.PubMed
10.
Brook I, Yocum P: In vitro protection of group A beta-hemolytic streptococci from penicillin and cephalothin by Bacteroides fragilis. Chemotherapy 1983, 29:18–23.CrossRefPubMed
11.
De Louvois J, Hurley R: Inactivation of penicillin by purulent exudates. Br Med J 1977, 2:998–1000.CrossRef
12.
Masuda G, Tomioka S: Possible beta-lactamase activities detectable in infective clinical specimens. J Antibiot (Tokyo) 1977, 30:1093–1097.
13.
O’Keefe JP, Tally FP, Barza M, Gorbach SL: Inactivation of penicillin-G during experimental infection with Bacteroides fragilis. J Infect Dis 1978, 137:437–442.PubMed
14.
Bryant RE, Rashad AL, Mazza JA, Hammond D: Beta-lactamase activity in human plus. J Infect Dis 1980, 142:594–601.PubMed
15.
Boughton WH: Rapid detection in spinal fluid of beta-lactamase produced by ampicillin-resistant Haemophilus influenzae. J Clin Microbiol 1982, 15:1167–1168.PubMed
16.
Brook I: Presence of beta-lactamase-producing bacteria and beta-lactamase activity in abscesses. Am J Clin Pathol 1986, 86:97–101.PubMed
17.
Brook I: Quantitative cultures and beta-lactamase activity in chronic suppurative otitis media. Ann Otol Rhinol Laryngol 1989, 98:293–297.PubMed
18.
Brook I, Yocum P: Bacteriology and beta-lactamase activity in ear aspirates of acute otitis media that failed amoxicillin therapy. Pediatr Infect Dis J 1995, 14:805–808.PubMedCrossRef
19.
Brook I, Yocum P, Frazier EH: Bacteriology and beta-lactamase activity in acute and chronic maxillary sinusitis. Arch Otolaryngol Head Neck Surg 1996, 122:418–422.PubMed
20.
Brook I, Gober AE: Monthly changes in the rate of recovery of penicillin-resistant organisms from children. Pediatr Infect Dis J 1997, 16:255–257.CrossRefPubMed
21.
Heimdahl A, Von Konow L, Nord CE: Isolations of beta-lactamase-producing Bacteroides strains associated with clinical failures with penicillin treatment of human orofacial infections. Arch Oral Biol 1980, 25:288–292.CrossRef
22.
Brook I: Beta-lactamase-producing bacteria recovered after clinical failures with various penicillin therapy. Arch Otolaryngol 1984, 110:228–231.PubMed
23.
•• Pichichero ME, Casey JR: Systematic review of factors contributing to penicillin treatment failure in Streptococcus pyogenes pharyngitis. Otolaryngol Head Neck Surg 2007, 137:851–857. The explanations for penicillin treatment failure in GABHS tonsillopharyngitis are reviewed in this article. These include carrier state, lack of compliance, recurrent exposure, in vivo copathogenicity of BL-producing normal pharyngeal flora, in vivo bacterial coaggregation, poor antibiotic penetration to tonsillopharyngeal tissue, in vivo eradication of normal protective flora, early initiation of antibiotic therapy resulting in suppression of an adequate host immune response, intracellular localization of GABHS, GABHS tolerance to penicillin, contaminated toothbrushes or orthodontic appliances, and transmission from the family pet. The authors concluded that the evidence base to support the proposed explanations is generally weak by current standards.CrossRefPubMed
24.
Livermore DM: Has the era of untreatable infections arrived? J Antimicrob Chemother 2009, 64(Suppl 1):i29–i36.CrossRefPubMed
25.
Septimus EJ, Kuper KM: Clinical challenges in addressing resistance to antimicrobial drugs in the twenty-first century. Clin Pharmacol Ther 2009, 86:336–339.CrossRefPubMed
26.
Smith TD, Huskins WC, Kim KS, Kaplan EL: Efficacy of beta-lactamase-resistant penicillin and influence of penicillin tolerance in eradicating streptococci from the pharynx after failure of penicillin therapy for group A streptococcal pharyngitis. J Pediatr 1987, 110:777–782.CrossRefPubMed
27.
Kaplan EL, Johnson DR: Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group A streptococci from children with acute pharyngitis. Pediatrics 2001, 108:1180–1186. CrossRefPubMed
28.
Tristram S, Jacobs MR, Appelbaum PC: Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007, 20:368–389. CrossRefPubMed
29.
Critchley IA, Brown SD, Traczewski MM, et al.: National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005–2006 US Faropenem surveillance study. Antimicrob Agents Chemother 2007, 51:4382–4389.CrossRefPubMed
30.
Knudsin RB, Miller JM: Significance of the Staphylococcus aureus carrier state in the treatment of disease due to group A streptococci. N Engl J Med 1964, 271:1395–1397.CrossRef
31.
Quie PG, Pierce AX, Wannamaker LW: Influence of penicillinase producing staphylococci on the eradication of group A streptococci from the upper respiratory tract by penicillin treatment. Pediatrics 1966, 37:467–476.PubMed
32.
Murphy TF, Parameswaran GI: Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 2009, 49:124–131.CrossRefPubMed
33.
Brook I, Yocum P, Friedman EM: Aerobic and anaerobic flora recovered from tonsils of children with recurrent tonsillitis. Ann Otol Rhinol Laryngol 1981, 90:261–263.PubMed
34.
Brook I, Yocum P: Bacteriology of chronic tonsillitis in young adults. Arch Otolaryngol 1984, 110:803–805.PubMed
35.
Brook I, Yocum P: Quantitative measurement of beta-lactamase levels in tonsils of children with recurrent tonsillitis. Acta Otolaryngol Scand 1984, 98:456–459.
36.
Reilly S, Timmis P, Beeden AG, Willis AT: Possible role of the anaerobe in tonsillitis. J Clin Pathol 1981, 34:542–547.CrossRefPubMed
37.
Chagollan JR, Macias JR, Gil JS: Flora indigena de las amigalas. Investigacion Medical Internacional 1984, 11:36–43.
38.
Tuner K, Nord CE: Beta lactamase-producing microorganisms in recurrent tonsillitis. Scand J Infect Dis Suppl 1983, 39:83–85.PubMed
39.
Tuner K, Nord CE: Emergence of beta-lactamase producing microorganisms in the tonsils during penicillin treatment. Eur J Clin Microb 1986, 5:399–404.CrossRef
40.
Brook I, Gober AE: Emergence of beta-lactamase-producing aerobic and anaerobic bacteria in the oropharynx of children following penicillin chemotherapy. Clin Pediatr 1984, 23:338–341.CrossRef
41.
Brook I: Emergence and persistence of β-lactamase-producing bacteria in the oropharynx following penicillin treatment. Arch Otolaryngol Head Neck Surg 1988, 114:667–670.PubMed
42.
Brook I, Gober AE: Prophylaxis with amoxicillin or sulfisoxazole for otitis media: effect on the recovery of penicillin-resistant bacteria from children. Clin Infect Dis 1996;22:143–145.PubMed
43.
Brook I: Role of beta-lactamase-producing bacteria in penicillin failure to eradicate group A streptococci. Pediatr Infect Dis 1985, 4:491–495.PubMedCrossRef
44.
Brook I, Gober AE: Failure to eradicate streptococci and beta-lactamase producing bacteria. Acta Paediatr 2008, 97:193–195.CrossRefPubMed
45.
Roos K, Grahn E, Holn SE: Evaluation of beta-lactamase activity and microbial interference in treatment failures of acute streptococcal tonsillitis. Scand J Infect Dis 1986, 18:313–318.CrossRefPubMed
46.
Brook I, Gober AE: Resistance to antimicrobials used for the therapy of otitis and sinusitis: effect of previous antimicrobial therapy and smoking. Ann Otol Rhinol Laryngol 1999, 108: 645–647.PubMed
47.
Breese BB, Disney FA, Talpey WB: Beta-hemolytic streptococcal illness: comparison of lincomycin, ampicillin and potassium penicillin-G in treatment. Am J Dis Child 1966, 112:21–27.PubMed
48.
Breese BB, Disney FA, Talpey WB, et al.: Beta-hemolytic streptococcal infection: comparison of penicillin and lincomycin in the treatment of recurrent infections or the carrier state. Am J Dis Child 1969, 117:147–152.PubMed
49.
Randolph MF, DeHaan RM: A comparison of lincomycin and penicillin in the treatment of group A streptococcal infections: speculation on the “L” forms as a mechanism of recurrence. Del Med J 1969, 41:51–62.PubMed
50.
Howie VM, Plousard JH: Treatment of group A streptococcal pharyngitis in children: comparison of lincomycin and penicillin G given orally and benzathine penicillin G given intramuscularly. Am J Dis Child 1971, 121:477.PubMed
51.
Randolph MF, Redys JJ, Hibbard EW: Streptococcal pharyngitis III. Streptococcal recurrence rates following therapy with penicillin or with clindamycin (7-chlorlincomycin). Del Med J 1970, 42:87–92.PubMed
52.
Stillerman M, Isenberg HD, Facklan RR: Streptococcal pharyngitis therapy: comparison of clindamycin palmitate and potassium phenoxymethyl penicillin. Antimicrob Agents Chemother 1973, 4:516–520.
53.
Massell BF: Prophylaxis of streptococcal infection and rheumatic fever: a comparison of orally administered clindamycin and penicillin. JAMA 1979, 241:1589–1594.CrossRefPubMed
54.
Brook I, Leyva F: The treatment of the carrier state of group A beta-hemolytic streptococci with clindamycin. Chemother 1981, 27:360–367.CrossRef
55.
Brook I, Hirokawa R: Treatment of patients with recurrent tonsillitis due to group A beta-hemolytic streptococci: a prospective randomized study comparing penicillin, erythromycin and clindamycin. Clin Pediatr 1985, 24:331–336.CrossRef
56.
Orrling A, Stjernquist-Desatnik A, Schalen C: Clindamycin in recurrent group A streptococcal pharyngotonsillitis—an alternative to tonsillectomy? Acta Otolaryngol 1997, 117:618–622.CrossRefPubMed
57.
Chaudhary S, Bilinsky SA, Hennessy JL, et al.: Penicillin V and rifampin for the treatment of group A streptococcal pharyngitis: a randomized trial of 10 days penicillin vs 10 days penicillin with rifampin during the final 4 days of therapy. J Pediatr 1985, 106:481–486.CrossRefPubMed
58.
Tanz RR, Shulman ST, Barthel MJ, et al.: Penicillin plus rifampin eradicate pharayngeal carrier of group A streptococci. J Pediatr 1985, 106:876–880.CrossRefPubMed
59.
Tanz RR, Poncher JR, Corydon KE, et al.: Clindamycin treatment of chronic pharyngeal carriage of group A streptococci. J Pediatr 1991, 119:123–128.CrossRefPubMed
60.
Brook I: Treatment of patients with acute recurrent tonsillitis due to group A beta-haemolytic streptococci: a prospective randomized study comparing penicillin and amoxycillin/clavulanate potassium. J Antimicrob Chemother 1989, 24:227–233.CrossRefPubMed
61.
Foote PA Jr, Brook I: Penicillin and clindamycin therapy in recurrent tonsillitis. Arch Otolaryngol Head Neck Surg 1989, 115:856–859.PubMed
62.
Brook I, Shah K, Jackson W: Microbiology of healthy and diseased adenoids. Laryngoscope 2000, 110:994–999.CrossRefPubMed
63.
Brook I, Shah K: Effect of amoxycillin with or without clavulanate on adenoid bacterial flora. J Antimicrob Chemother 2001, 48:269–273.CrossRefPubMed
64.
Brook I, Shah K: Effect of amoxicillin or clindamycin on the adenoids bacterial flora. Otolaryngol Head Neck Surg 2003, 129:5–10.CrossRefPubMed
65.
Brook I, Gober AE: Effect of amoxicillin and co-amoxiclav on the aerobic and anaerobic nasopharyngeal flora. J Antimicrob Chemother 2002, 49:689–692.CrossRefPubMed
66.
Levison ME, Mangura CT, Lorber B, et al.: Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann Int Med 1983, 98:466–471. PubMed
67.
Gudiol F, Manresa F, Pallares R, et al.: Clindamycin vs penicillin for anaerobic lung infections. High rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. Arch Intern Med 1990, 150:2525–2529.
68.
Brook I: Treatment of aspiration or tracheostomy-associated pneumonia in neurologically impaired children: effect of antimicrobials effective against anaerobic bacteria. Int J Pediatr Otorhinolaryngol 1996, 35:171–177. CrossRefPubMed
69.
Brook I, Foote PA: Isolation of methicillin resistant Staphylococcus aureus from the surface and core of tonsils in children. Int J Pediatr Otorhinolaryngol 2006, 70:2099–2102. CrossRefPubMed
70.
Brook I: Role of methicillin-resistant Staphylococcus aureus in head and neck infections. J Laryngol Otol 2009, 11:1–7.
Metadata
Title
β-Lactamase–Producing Bacteria in Upper Respiratory Tract Infections
Author
Itzhak Brook
Publication date
01-03-2010
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 2/2010
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-010-0081-8

Other articles of this Issue 2/2010

Current Infectious Disease Reports 2/2010 Go to the issue

Clinical Trial Report

The Next Era of HCV Antiviral Therapy Finally Begins: Part 1

ReviewPaper

Evaluation and Management of Anal Intraepithelial Neoplasia in HIV-Negative and HIV-Positive Men Who Have Sex with Men

ReviewPaper

Epidemic of Sexually Transmitted Hepatitis C Virus Infection Among HIV-Infected Men

ReviewPaper

Update on HHV-8-Associated Malignancies

ReviewPaper

Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infection (PANDAS): a Controversial Diagnosis

Clinical Trial Report

The Next Era of HCV Antiviral Therapy Finally Begins: Part 2
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits